2005 News Archive

Notification of Directors~ interests
22 December 2005

Notification of PDMR interests
22 December 2005

Notification of major interests in shares
17 December 2005
Protherics PLC (the Company), the biopharmaceutical company focused on critical care and oncology, received notification on 15 December 2005 from AXA Investment Managers UK Limited on behalf of AXA S.A. and its Group companies (the AXA Group) that the consolidated holding of the AXA Group on 14 December 2005 was 31,869,803 ordinary 2p shares (Ordinary Shares) in the capital of the Company (12.976%).

Interim results for the six months to 30 September 2005
08 December 2005
Protherics PLC, (“Protherics” or the “Company”) the biopharmaceutical company focused on critical care and oncology, today announces its interim results for the six months to 30 September 2005.

Transition to international financial reporting standards (IFRS)
08 December 2005
The Group’s financial statements for the year ended 31 March 2006 will be the first annual financial statements that comply with International Financial Reporting Standards (IFRS). The Group’s financial statements prior to and including 31 March 2005 had been prepared in accordance with Generally Accepted Accounting Principles in the United Kingdom (UK GAAP).

Protherics and AstraZeneca Announce Late Stage Licensing Agreement CytoFab™ For Treatment of Sepsis
08 December 2005
Protherics, the biopharmaceutical company focused on critical care and oncology, today announces an agreement with AstraZeneca for the global development and commercialisation of Protherics’ anti-sepsis product CytoFab™. CytoFab™ is currently being prepared for a single phase III registration study in severe sepsis in line with guidance received at an end of phase II meeting with the US Food and Drug Administration (FDA).

Notification of interim results
05 December 2005
Protherics plc (“Protherics”), the biopharmaceutical company focused on critical care and oncology, will be announcing its interim results for the six months ended 30 September 2005, on Thursday 8 December 2005.

Notification of major interests in shares
04 November 2005
Protherics PLC (the “Company”), the biopharmaceutical company focused on critical care and oncology, received notification on 2 November 2005 from AXA Investment Managers UK Limited on behalf of AXA S.A. and its Group companies (the “AXA Group”), the consolidated holding of the AXA Group on 2 November 2005 was 31,166,615 ordinary 2p shares (“Ordinary Shares”) in the capital of the Company (12.72%).

Notification of major interests in shares
18 October 2005
Protherics PLC (“Protherics” or the “Company”), the biopharmaceutical company focused on critical care and oncology, received notification on 17 October 2005 on behalf of Perpetual Income & Growth Investment Trust plc (“Perpetual”) that, following the purchase of 760,000 Ordinary Shares of 2p each in the Company (“Ordinary Shares”)

Protherics PLC Block Listing
07 October 2005
Protherics PLC (“Protherics” or the “Company”) made an application to London Stock Exchange plc and the UK Listing Authority on 7 April 2005 for the block listing of 5,853,134 ordinary shares which may be exercised under the Company’s various share option schemes and individual share option agreements (the “Schemes”)

Notification of major interests in shares
07 October 2005
Protherics PLC (“the Company”) has received notification on 6 October 2005 on behalf of Fidelity International Limited and its direct and indirect subsidiaries (being non-beneficial holders) that they have disclosable interests in 11,691,607 ordinary shares, representing 4.77 % of the issued share capital of the Company.

Notification of major interests in shares
07 October 2005
Protherics PLC (“the Company”) has received notification on 7 October 2005 on behalf of Framlington Investment Management Limited that it has a disclosable interest in 30,106,615 ordinary shares, representing 12.29 % of the issued share capital of the Company.

Protherics ADRS Commence Trading on NASDAQ and UBS Conference, New York
27 September 2005
Protherics PLC (“Protherics” or the “Company”), the biopharmaceutical company focused on critical care and oncology, announces today that the Company’s American Depositary Receipts have commenced trading on The NASDAQ National Market effective today under the ticker symbol PTIL. Protherics also announces that it will present at the UBS Global Life Sciences Conference at 4:30 p.m. Eastern Time on Thursday, September 29, 2005 at The Grand Hyatt Hotel in New York, NY.

Protherics announces NASDAQ ADR listing
23 September 2005
London, 23 September 2005: Protherics PLC (“Protherics”), the biopharmaceutical company focused on critical care and oncology, today announces that it has received preliminary approval from The NASDAQ Stock Market to establish a Level II American Depository Receipt (“ADR”) program in the US. The Bank of New York has been appointed as the depositary bank to administer the ADR program.

Notification of major interests in shares
09 August 2005
Protherics PLC (“the Company”) has received notification on 8 August 2005 on behalf of Aviva plc and Morley Fund Management Limited (a subsidiary of Aviva plc) that they have a material interest in 12,460,031 ordinary shares, representing 5.12 % of the issued share capital of the Company, and a total interest in 27,332,004 ordinary shares, representing 11.23% of the issued share capital of the Company. This increase follows a purchase of 1,314,449 ordinary shares on 5 August 2005.

Block Listing
08 August 2005
As set out in the listing particulars published by Protherics PLC (“the Company”) on 20 January 2005, convertible loan notes of £1 each in the capital of the Company (“Convertible Loan Notes”) became convertible into Ordinary Shares on 20 December 2004.

Viraxaze™ EU marketing autorisation submitted
28 July 2005
Protherics PLC (“Protherics” or the “Company”), the international biopharmaceutical company focused on critical care and oncology, today announces that it has submitted a marketing authorisation application (“MAA”) in the European Union (“EU”) for Voraxaze™. Voraxaze is an adjunctive therapy for patients experiencing, or at risk of, toxicity from methotrexate (“MTX”), a widely used anti-cancer agent.

Appointment of Non-Executive Director
27 July 2005
Protherics PLC (“Protherics”), the international biopharmaceuticals company, is pleased to announce the appointment of Bryan Morton as a non-executive director, with effect from 1 August 2005.

Results of AGM
20 July 2005
The Company is pleased to announce that at the Annual General Meeting, which was held on 20 July 2005, resolutions 1 to 7 were duly passed.

Notification of PDMR interests
20 July 2005
Protherics PLC (“the Company”) announces the award on 19 July 2005, under the Protherics PLC 2005 Long Term Incentive Plan, of a conditional right to receive 100,251 ordinary shares in the Company to Saul Komisar, the President of the Company’s US operations. The awards vest, subject to the achievement of the performance conditions, on the third anniversary of the date of grant.

Board Changes
20 July 2005
Protherics PLC (“Protherics”), the international biopharmaceutical company, announces that David Gration has resigned from the Board following today’s Annual General Meeting.

AGM Statement
20 July 2005
At the Annual General Meeting today, Stuart Wallis, Chairman, told shareholders.

Notification of major interest in shares
30 June 2005

Preliminary Results for Year Ended 31 March 2005
07 June 2005
Protherics PLC, the international biopharmaceutical company, today announces its preliminary results for the twelve months to 31 March 2005.

Protherics Announces European Patent Granted for Angiotensin Vaccine
07 June 2005
Protherics PLC, the international biopharmaceutical company, today announces that it has been granted a European patent for Angiotensin Vaccine. Angiotensin Vaccine is being developed for the treatment of hypertension (high blood pressure) and has shown encouraging clinical results in early trials inducing antibodies against angiotensin. Inhibition of angiotensin is known to reduce blood pressure.

Board Changes
07 June 2005
Protherics PLC (“Protherics”), the international biopharmaceutical company, announces that David Gration is to step down from the board following the Annual General Meeting to be held on 20 July 2005.

Notification of Major Interest in Shares
19 May 2005
The Company has received notification on 18 May 2005 informing it that Legal and General Group plc has a notifiable interest in 7,622,374 ordinary shares, representing 3.15% of the issued share capital of the Company.

Notification of major interests in shares
13 May 2005
The Company has received notification on 13 May 2005 on behalf of Aviva plc and on behalf of Morley Fund Management Limited, informing it that, following a purchase of 130,000 ordinary shares on 11 May 2005.

Notification of Preliminary Results
09 May 2005
Protherics plc (“Protherics”), the international biopharmaceutical company, will be announcing its preliminary results for the year ended 31 March 2005, on Tuesday 7 June 2005. An analyst meeting will be held at 9.30am at the offices of Financial Dynamics, 26 Southampton Buildings, London, WC2A 1PB.

Notification of major interests in shares
21 April 2005
The Company has received notification on 20 April 2005 from Framlington Investment Management Limited informing it that they have an interest in 26,195,315 ordinary shares, representing 10.81% of the issues share capital of the Company.

Notification of major interests in shares
21 April 2005
The Company has received notification on 21 April 2005 from Aviva plc on behalf of Morley Fund Management Limited informing it that, following a purchase of 642,000 ordinary shares on 19 April 2005, they have an interest in 9,979,742 ordinary shares, representing 4.12 % of the issues share capital of the Company.

Board Change
19 April 2005
Protherics PLC (“Protherics”), the international biopharmaceutical company, announces the resignation today of Dr Tony Atkinson as a non-executive director.

Notification of interests of Director
08 April 2005
Schedule 11 Notification of Directors share interests

Application for Block Listing
07 April 2005

Director Shareholding
31 March 2005
Director purchase of shares

Notification of major interest in shares
30 March 2005
Perpetual Income & Growth Investment Trust plc announce acquisition of 750,000 ordinary shares.

NQO2: US patent granted and trial update
24 March 2005
Grant of patent in the US for its selective chemotherapy treatment, NQO2

Notification of interests of Directors
01 March 2005
Following the approval by shareholders of new Executive Compensation Arrangements at the EGM held on 27 January 2005

FDA Approves Alternative Filling,Freeze-Drying and Packaging Contractor for Digifab™
17 February 2005
Protherics plc ("Protherics"), the international biopharmaceutical company, today announces that the US Food and Drug Administration ("FDA") has approved an alternative third party contractor, Chesapeake Biological laboratories, Inc. ("CBL"), to fill, freeze-dry and package Digifab™.

Declaration of Interest in shares
15 February 2005
The Company was informed by Artemis Investment Management Ltd.

Block Listing
07 February 2005
As set out in the listing particulars published by the Company on 20 January 2005, the convertible load notes of £1 each in the capital of the Company (“Convertible Loan Notes”) became convertible into ordinary shares in the capital of the Company (“Ordinary Shares”) on 20 December 2004.

Notification of major interests in shares
27 January 2005
Notification of Share Holdings by Fidelity International Ltd

Result of EGM
27 January 2005
Result of the Extraordinary General Meeting held today

Director Shareholding
21 January 2005

Notification of Interest in Shares
20 January 2005
Notification of Major Share Interest by Fidelity International Limited

Notice of submission of Listing Particulars to UKLA
20 January 2005
Notice of submission of Listing Particulars to UKLA. Please see attached document.

Press Release
17 January 2005
Notification of interests of Directors and connected persons

FDA Approves Alternative Filling, Freeze-Drying And Packaging Contractor For CroFab™
14 January 2005
Protherics plc (“Protherics”), the international biopharmaceutical company, today announces that the US Food and Drug Administration (FDA) has approved an alternative third party contractor, Chesapeake Biological Laboratories Inc. (CBL), to fill, freeze dry and package CroFab™.

Notification of major interests in shares
04 January 2005
Following purchases of 628,961 ordinary shares on 23 December 2004, the Company has received notification on behalf of Aviva plc and Morley Fund Management Limited that their aggregate material interests increased to 7,370,481 ordinary shares representing 3.22% of the issued share capital of the Company.


2007 News
2006 News Archive
2005 News Archive
2004 News Archive
2003 News Archive
2002 News Archive
2001 News Archive
2000 News Archive